Gossamer Bio, Inc.
NASDAQ: GOSS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Faheem Hasnain
- Employees
- 162
- Headquarters
- San Diego, United States
- IPO year
- 2019
- Market cap
- $39.6M
- Website
- https://www.gossamerbio.com
Loading GOSS…
Loading profile data…Frequently asked questions about GOSS
What does Gossamer Bio, Inc. (GOSS) do?
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin fa...
Where does GOSS trade?
Gossamer Bio, Inc. (GOSS) trades on the NASDAQ.
What sector is GOSS in?
Gossamer Bio, Inc. (GOSS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Gossamer Bio, Inc.?
Faheem Hasnain is the chief executive officer of Gossamer Bio, Inc. (GOSS).
Where is Gossamer Bio, Inc. headquartered?
Gossamer Bio, Inc. is headquartered in United States.
Does GOSS pay a dividend?
Gossamer Bio, Inc. (GOSS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GOSS go public?
Gossamer Bio, Inc. (GOSS) completed its initial public offering in 2019.